Lipantil Nano

Fenofibrate, the active ingredient in Lipantil Nano, is a fibrate presented as a nanonised oral formulation for oral use. It treats hypertriglyceridaemia, mixed dyslipidaemia and primary hypercholesterolaemia as adjunct therapy in adults.

GNH USA supplies Lipantil Nano as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fenofibrate acts on lipid metabolism pathways to lower abnormal blood fats. - Hypertriglyceridaemia: reduces elevated triglyceride levels. - Mixed dyslipidaemia: improves overall lipid profile by lowering triglycerides and modestly affecting cholesterol. - Primary hypercholesterolaemia (adjunct therapy): assists statin therapy to further lower lipid concentrations.

Fenofibrate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increase in ALT/AST. - Muscle cramps: mild myalgia without weakness. - Rash: mild skin irritation or itching.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with weakness and dark urine. - Hepatotoxicity: significant liver injury with jaundice. - Severe allergic reaction: anaphylaxis or angioedema. - Gallstones: formation of biliary sludge or stones. - Blood dyscrasias: thrombocytopenia or leukopenia.

When prescribing Fenofibrate, clinicians should consider several precautionary measures to minimise risk. - Liver function monitoring: assess baseline and periodic ALT/AST levels. - Renal function assessment: evaluate creatinine clearance before initiation. - Muscle toxicity vigilance: advise patients to report unexplained muscle pain or weakness. - Drug interactions review: avoid concomitant use with strong CYP2C8 inhibitors without dose adjustment. - Pregnancy and lactation caution: use only if potential benefit outweighs risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Fenofibrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Gemfibrozil: combined use markedly increases risk of rhabdomyolysis. - Strong CYP2C8 inhibitors (e.g., clopidogrel): may raise fenofibrate plasma levels. - Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Statins (especially high‑dose simvastatin): increased risk of myopathy; monitor CK. - Bile acid sequestrants: may reduce fenofibrate absorption; separate dosing by at least 1 hour. - Immunosuppressants (e.g., cyclosporine): may affect lipid metabolism; monitor lipid levels.